LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 110 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $119,534 | -16.3% | 101,300 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $142,833 | -6.0% | 101,300 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $151,950 | +28.2% | 101,300 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $118,521 | +4.0% | 101,300 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $114,000 | -28.8% | 101,300 | 0.0% | 0.00% | -33.3% |
| Q2 2022 | $160,000 | +2.6% | 101,300 | 0.0% | 0.00% | +50.0% |
| Q1 2022 | $156,000 | -37.1% | 101,300 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $248,000 | +4.2% | 101,300 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $238,000 | +33.7% | 101,300 | 0.0% | 0.00% | +33.3% |
| Q4 2020 | $178,000 | +87.4% | 101,300 | 0.0% | 0.00% | +50.0% |
| Q3 2020 | $95,000 | +8.0% | 101,300 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $88,000 | +4.8% | 101,300 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $84,000 | -6.7% | 101,300 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $90,000 | -10.0% | 101,300 | -0.4% | 0.00% | 0.0% |
| Q3 2019 | $100,000 | – | 101,661 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $83,313,000 | 5.12% |
| Defender Capital, LLC. | 4,997,870 | $12,245,000 | 3.92% |
| Raffles Associates | 543,590 | $1,332,000 | 1.28% |
| Prescott General Partners LLC | 1,851,851 | $4,537,000 | 0.16% |
| DCF Advisers, LLC | 85,000 | $208,000 | 0.08% |
| Long Focus Capital Management, LLC | 215,000 | $527,000 | 0.07% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $110,000 | 0.06% |
| DAFNA Capital Management LLC | 80,000 | $196,000 | 0.05% |
| Strategic Wealth Investment Group, LLC | 65,069 | $159,000 | 0.04% |
| Fort Sheridan Advisors LLC | 52,931 | $130,000 | 0.04% |